PDF
ePub
Citation
Print
Abstract
Development of luminex-based solid phase assays enables advanced measurement of HLA antibody with sensitivity, specificity, and increasing knowledge of unacceptable antigens. In this review, we described the principle of the luminex-based assay and its current applications for organ transplantation including C1q assay, calculated panel reactive antibody, and virtual cross-matching. We also discussed the technical aspects and limitations for clinical utilization. The variables related to measurement of HLA antibody specificities and their clinical relevance remain unclear, therefore the interpretation of results requires compre-hensive knowledge and clinical information in critical cases.
References
1). Einecke G, Sis B, Reeve J, Mengel M, Campbell PM, Hidalgo LG, et al. Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure. Am J Transplant. 2009; 9:2520–31.
2). Sellaré s J, de Freitas DG, Mengel M, Reeve J, Einecke G, Sis B, et al. Understanding the causes of kidney transplant failure: the dominant role of antibody-mediated rejection and nonadherence. Am J Transplant. 2012; 12:388–99.
3). Sü sal C, Dö hler B, Sadeghi M, Ovens J, Opelz G. HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report. Transplantation. 2009; 87:1367–71.
4). Trajanoski D, Fidler SJ. HLA typing using bead-based methods. Methods Mol Biol. 2012; 882:47–65.
5). El-Awar N, Lee J, Terasaki PI. HLA antibody identification with single antigen beads compared to conventional methods. Hum Immunol. 2005; 66:989–97.
6). Colombo MB, Haworth SE, Poli F, Nocco A, Puglisi G, Innocente A, et al. Luminex technology for anti-HLA antibody screening: evaluation of performance and of impact on laboratory routine. Cytometry B Clin Cytom. 2007; 72:465–71.
7). Ozawa M, Rebellato LM, Terasaki PI, Tong A, Briley KP, Catrou P, et al. Longitudinal testing of 266 renal allograft patients for HLA and MICA antibodies: Greenville experience. Clin Transpl. 2006. 265–90.
8). DeVos JM, Gaber AO, Knight RJ, Land GA, Suki WN, Gaber LW, et al. Donor-specific HLA-DQ antibodies may contribute to poor graft outcome after renal transplantation. Kidney Int. 2012; 82:598–604.
9). Tagliamacco A, Cioni M, Comoli P, Ramondetta M, Brambilla C, Trivelli A, et al. DQ molecules are the principal stim-ulators of de novo donor-specific antibodies in nonsen-sitized pediatric recipients receiving a first kidney transplant. Transpl Int. 2014; 27:667–73.
10). Murphey CL, Bingaman AW. Histocompatibility considerations for kidney paired donor exchange programs. Curr Opin Organ Transplant. 2012; 17:427–32.
11). Caro-Oleas JL, Gonzá lez-Escribano MF, Gonzá lez-Roncero FM, Acevedo-Calado MJ, Cabello-Chaves V, Gentil-Govantes MÁ, et al. Clinical relevance of HLA donor-specific antibodies detected by single antigen assay in kidney transplantation. Nephrol Dial Transplant. 2012; 27:1231–8.
12). Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, et al. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010; 21:1398–406.
13). Freitas MC, Rebellato LM, Ozawa M, Nguyen A, Sasaki N, Everly M, et al. The role of immunoglobulin-G subclasses and C1q in de novo HLA-DQ donor-specific antibody kidney transplantation outcomes. Transplantation. 2013; 95:1113–9.
14). Zeevi A, Lunz J, Feingold B, Shullo M, Bermudez C, Teuteberg J, et al. Persistent strong anti-HLA antibody at high titer is complement binding and associated with increased risk of antibody-mediated rejection in heart transplant recipients. J Heart Lung Transplant. 2013; 32:98–105.
15). Crespo M, Torio A, Mas V, Redondo D, Pé rez-Sá ez MJ, Mir M, et al. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter? Transpl Immunol. 2013; 29:28–33.
16). Bray RA, Nolen JD, Larsen C, Pearson T, Newell KA, Kokko K, et al. Transplanting the highly sensitized patient: The emory algorithm. Am J Transplant. 2006; 6:2307–15.
17). Dunn TB, Noreen H, Gillingham K, Maurer D, Ozturk OG, Pruett TL, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011; 11:2132–43.
18). Otten HG, Verhaar MC, Borst HP, Hené RJ, van Zuilen AD. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant. 2012; 12:1618–23.
19). Claas FH, Witvliet MD, Duquesnoy RJ, Persijn GG, Doxiadis II. The acceptable mismatch program as a fast tool for highly sensitized patients awaiting a cadaveric kidney transplantation: short waiting time and excellent graft outcome. Transplantation. 2004; 78:190–3.
20). Tait BD, Sü sal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation. 2013; 95:19–47.
21). Konvalinka A, Tinckam K. Utility of HLA antibody testing in kidney transplantation. J Am Soc Nephrol [in press 2015 Mar 24].
22). Schnaidt M, Weinstock C, Jurisic M, Schmid-Horch B, Ender A, Wernet D. HLA antibody specification using single-antigen beads-a technical solution for the prozone effect. Transplantation. 2011; 92:510–5.
23). Weinstock C, Schnaidt M. The complement-mediated prozone effect in the Luminex single-antigen bead assay and its impact on HLA antibody determination in patient sera. Int J Immunogenet. 2013; 40:171–7.
24). Kosmoliaptsis V, Bradley JA, Peacock S, Chaudhry AN, Taylor CJ. Detection of immunoglobulin G human leukocyte antigen-specific alloantibodies in renal transplant patients using single-antigen-beads is compromised by the presence of immunoglobulin M human leukocyte antigen-specific alloantibodies. Transplantation. 2009; 87:813–20.
25). Ravindranath MH, Kaneku H, El-Awar N, Morales-Buenrostro LE, Terasaki PI. Antibodies to HLA-E in nonalloimmunized males: pattern of HLA-Ia reactivity of an-ti-HLA-E-positive sera. J Immunol. 2010; 185:1935–48.
26). Ravindranath MH, Taniguchi M, Chen CW, Ozawa M, Kaneku H, El-Awar N, et al. HLA-E monoclonal antibodies recognize shared peptide sequences on classical HLA class Ia: relevance to human natural HLA antibodies. Mol Immunol. 2010; 47:1121–31.
27). Zachary AA, Lucas DP, Detrick B, Leffell MS. Naturally occurring interference in Luminex assays for HLA-specific antibodies: characteristics and resolution. Hum Immunol. 2009; 70:496–501.
28). Tait BD, Hudson F, Brewin G, Cantwell L, Holdsworth R. Solid phase HLA antibody detection technology-challenges in interpretation. Tissue Antigens. 2010; 76:87–95.
29). Lachmann N, Todorova K, Schulze H, Schö nemann C. Luminex(®) and its applications for solid organ transplantation, hematopoietic stem cell transplantation, and transfusion. Transfus Med Hemother. 2013; 40:182–9.
30). Cai J, Terasaki PI, Anderson N, Lachmann N, Schö nemann C. Intact HLA not beta2m-free heavy chain-specific HLA class I antibodies are predictive of graft failure. Transplantation. 2009; 88:226–30.
31). Pereira S, Perkins S, Lee JH, Shumway W, LeFor W, Lopez-Cepero M, et al. Donor-specific antibody against denatured HLA-A1: clinically nonsignificant? Hum Immunol. 2011; 72:492–8.
32). Gombos P, Opelz G, Scherer S, Morath C, Zeier M, Schemmer P, et al. Influence of test technique on sensitization status of patients on the kidney transplant waiting list. Am J Transplant. 2013; 13:2075–82.
33). Morales-Buenrostro LE, Terasaki PI, Marino-Vá zquez LA, Lee JH, El-Awar N, Alberú J. “Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males. Transplantation. 2008; 86:1111–5.
34). El-Awar N, Terasaki PI, Nguyen A, Sasaki N, Morales-Buenrostro LE, Saji H, et al. Epitopes of human leukocyte antigen class I antibodies found in sera of normal healthy males and cord blood. Hum Immunol. 2009; 70:844–53.
35). Poli F, Benazzi E, Innocente A, Nocco A, Cagni N, Gianatti A, et al. Heart transplantation with donor-specific antibodies directed toward denatured HLA-A*02: 01: a case report. Hum Immunol. 2011; 72:1045–8.
36). Goodridge JP, Burian A, Lee N, Geraghty DE. HLA-F and MHC class I open conformers are ligands for NK cell Ig-like receptors. J Immunol. 2013; 191:3553–62.
37). Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, et al. HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol. 2013; 191:1567–77.
38). Reed EF, Rao P, Zhang Z, Gebel H, Bray RA, Guleria I, et al. Comprehensive assessment and standardization of solid phase multiplex-bead arrays for the detection of antibodies to HLA. Am J Transplant. 2013; 13:1859–70.
39). Gandhi MJ, Carrick DM, Jenkins S, De Goey S, Ploeger NA, Wilson GA, et al. Lot-to-lot variability in HLA antibody screening using a multiplexed bead-based assay. Transfusion. 2013; 53:1940–7.
40). Friedlander R, Putheti P, Diaz E, Menon A, Ponce B, Muthukumar T, et al. On the detection of anti-HLA antibodies using single antigen bead Luminex assay: lot-to-lot variations in MFI. Transplantation. 2013; 96:e24–6.
41). Chin C, Chen G, Sequeria F, Berry G, Siehr S, Bernstein D, et al. Clinical usefulness of a novel C1q assay to detect immunoglobulin G antibodies capable of fixing complement in sensitized pediatric heart transplant patients. J Heart Lung Transplant. 2011; 30:158–63.
42). Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, et al. Complement-binding an-ti-HLA antibodies and kidney-allograft survival. N Engl J Med. 2013; 369:1215–26.
43). Sutherland SM, Chen G, Sequeira FA, Lou CD, Alexander SR, Tyan DB. Complement-fixing donor-specific antibodies identified by a novel C1q assay are associated with allograft loss. Pediatr Transplant. 2012; 16:12–7.
44). Llorente S, Boix F, Eguia J, Ló pez M, Bosch A, Martinez H, et al. C1q-fixing human leukocyte antigen assay in immunized renal patients: correlation between Luminex SAB-C1q and SAB-IgG. Transplant Proc. 2012; 44:2535–7.
45). Schaub S, Hö nger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation. 2014; 98:387–93.
46). Jang JY, Kim YJ, Kim Y, Park YJ, Han K, Oh EJ. Application of calculated panel reactive antibody using HLA frequencies in Koreans. Ann Lab Med. 2012; 32:66–72.
47). Sü sal C, Opelz G, Morath C. Role and value of Luminex(®)-detected HLA antibodies before and after kidney transplantation. Transfus Med Hemother. 2013; 40:190–5.
48). Morath C, Beimler J, Opelz G, Ovens J, Scherer S, Schmidt J, et al. An integrative approach for the transplantation of high-risk sensitized patients. Transplantation. 2010; 90:645–53.
49). Van den Berg-Loonen EM, Billen EV, Voorter CE, van Heurn LW, Claas FH, van Hooff JP, et al. Clinical relevance of pretransplant donor-directed antibodies detected by single antigen beads in highly sensitized renal transplant patients. Transplantation. 2008; 85:1086–90.
50). Sü sal C, Ovens J, Mahmoud K, Dö hler B, Scherer S, Ruhenstroth A, et al. No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report. Transplantation. 2011; 91:883–7.
51). Cecka JM. Current methodologies for detecting sensitization to HLA antigens. Curr Opin Organ Transplant. 2011; 16:398–403.
52). Archdeacon P, Chan M, Neuland C, Velidedeoglu E, Meyer J, Tracy L, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant. 2011; 11:896–906.
53). Oh EJ, Park H, Park KU, Kang ES, Kim HS, Song EY. Interlaboratory comparison of the results of lifecodes LSA class I and class II single antigen kits for human leukocyte antigen antibody aetection. Ann Lab Med. 2015; 35:321–8.
Table 1.
Characteristics of three beads for luminex-based HLA antibody tests
XML Download